##### Table of Contents



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549
 FORM 10-Q
 þ
    
    QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 For the quarterly period ended March 31, 2011
 or
 o
    
    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 For the transition period from                    to
 Commission file number: 000-54192
 REVA MEDICAL, INC.
  Delaware
    
    33-0810505(State or other jurisdiction of
    
    (I.R.S. Employerincorporation or organization)
    
    Identification No.)5751 Copley Drive, Suite B
    
    (858) 966-3000San Diego, CA 92111
    
    (Registrants telephone number,(Address of principal executive offices)
    
    including area code)
 þ o
 o o
  Large accelerated filer o
    
    Accelerated filer o
    
    Non-accelerated filer þ
    
    Smaller reporting company o
 o þ




---



##### 



REVA MEDICAL, INC.
 FORM 10-Q  QUARTERLY REPORT
For the Quarter Ended March 31, 2011
 Table of Contents
 PagePART I. FINANCIAL INFORMATION
    
    
    1Item 1. Consolidated Financial Statements
    
    
    1Item 2. Managements Discussion and Analysis of Financial Condition and Results of
Operations
    
    
    9Item 3. Quantitative and Qualitative Disclosures about Market Risk
    
    
    15Item 4. Controls and Procedures
    
    
    16PART II. OTHER INFORMATION
    
    
    17Item 1. Legal Proceedings
    
    
    17Item 1A. Risk Factors
    
    
    17Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
    
    
    18Item 3. Defaults upon Senior Securities
    
    
    19Item 4. (Removed and Reserved)
    
    
    19Item 5. Other Information
    
    
    19Item 6. Exhibits
    
    
    19SIGNATURES
    
    
    20EX-31.1EX-31.2EX-32.1
  REFERENCES
 Corporate Information
 www.revamedical.com
 Currency
  Trademarks
 ReZolve tm
 i




---



##### Table of Contents



PART I. FINANCIAL INFORMATION
 
 Item 1. Consolidated Financial Statements
 REVA Medical, Inc.   Consolidated Balance Sheets
 March 31,December 31,
    
    
    20112010
    
    
    (Unaudited)AssetsCurrent Assets:Cash and cash equivalents
    
    $
    81,747
    
    
    $
    77,734Prepaid expenses and other current assets
    
    
    765
    
    
    
    319Total current assets
    
    
    82,512
    
    
    
    78,053Property and equipment, net
    
    
    963
    
    
    
    1,028Total Assets
    
    $
    83,475
    
    
    $
    79,081Liabilities and Stockholders EquityCurrent Liabilities:Accounts payable
    
    $
    937
    
    
    $
    699Accrued expenses and other current liabilities
    
    
    591
    
    
    
    825Total Current Liabilities and Total Liabilities
    
    
    1,528
    
    
    
    1,524Commitments and Contingencies (Note 5)Stockholders Equity:Common stock  $0.0001 par value; 100,000,000 shares authorized at December 31, 2010
and March 31, 2011; 32,760,503 and 32,773,803 shares issued and outstanding at
December 31, 2010 and March 31, 2011, respectively
    
    
    3
    
    
    
    3Class B common stock  $0.0001 par value; 25,000,000 shares authorized at December 31, 2010
and March 31, 2011; no shares issued or outstanding
    
    
    
    
    
    
    Undesignated preferred stock  $0.0001 par value; 5,000,000 shares authorized at December
31, 2010 and March 31, 2011; no shares issued or outstanding
    
    
    
    
    
    
    Additional paid-in capital
    
    
    210,847
    
    
    
    211,589Accumulated other comprehensive income
    
    
    
    
    
    
    1Deficit accumulated during the development stage
    
    
    (128,903
    )
    
    
    (134,036
    )Total Stockholders Equity
    
    
    81,947
    
    
    
    77,557Total Liabilities and Stockholders Equity
    
    $
    83,475
    
    
    $
    79,081
  - 1 -




---



##### Table of Contents



REVA Medical, Inc.   Consolidated Statements of Operations
 Period fromJune 3, 1998(inception) toThree Months Ended March 31,
    
    
    March 31,2010
    
    
    2011
    
    
    2011Operating Expense:Research and development
    
    $
    1,863
    
    
    $
    3,241
    
    
    $
    77,562General and administrative
    
    
    368
    
    
    
    1,928
    
    
    
    22,120Loss from operations
    
    
    (2,231
    )
    
    
    (5,169
    )
    
    
    (99,682
    )Other Income (Expense):Interest income
    
    
    1
    
    
    
    46
    
    
    
    1,141Related party interest expense
    
    
    (378
    )
    
    
    
    
    
    
    (21,113
    )Interest expense
    
    
    (11
    )
    
    
    
    
    
    
    (952
    )Interest from amortization of notes payable premium
    
    
    
    
    
    
    
    
    
    
    2,283Gain (loss) on change in fair value of preferred
stock rights and warrant liabilities
    
    
    (375
    )
    
    
    
    
    
    
    1,795Loss on extinguishment of notes payable
    
    
    
    
    
    
    
    
    
    
    (13,285
    )Other income (expense)
    
    
    18
    
    
    
    (10
    )
    
    
    (50
    )Net Loss
    
    
    (2,976
    )
    
    
    (5,133
    )
    
    
    (129,863
    )Cumulative dividends and deemed dividends on
Series H convertible preferred stock
    
    
    (655
    )
    
    
    
    
    
    
    (10,695
    )Net Loss Attributable to Common Stockholders
    
    $
    (3,631
    )
    
    $
    (5,133
    )
    
    $
    (140,558
    )Net Loss Per Common Share:Net loss per share, basic and diluted
    
    $
    (1.33
    )
    
    $
    (0.16
    )Shares used to compute net loss per share,
basic and diluted
    
    
    2,740,164
    
    
    
    32,764,335
  - 2 -




---



##### Table of Contents



REVA Medical, Inc.   Consolidated Statements of Cash Flows
 
 Period fromJune 3, 1998(inception) toThree Months Ended March 31,
    
    
    March 31,2010
    
    
    2011
    
    
    2011Cash Flows from Operating Activities:Net loss
    
    $
    (2,976
    )
    
    $
    (5,133
    )
    
    $
    (129,863
    )Non-cash adjustments to reconcile net loss to net cash used for
operating activities:Depreciation and amortization
    
    
    124
    
    
    
    116
    
    
    
    2,957Loss (gain) on property and equipment disposal and impairment
    
    
    
    
    
    
    (1
    )
    
    
    584Stock-based compensation
    
    
    75
    
    
    
    737
    
    
    
    2,765Interest on notes payable
    
    
    388
    
    
    
    
    
    
    
    8,562Repayment premium on notes payable
    
    
    
    
    
    
    
    
    
    
    11,100Loss on change in fair value of preferred stock warrant liability
    
    
    375
    
    
    
    
    
    
    
    970Gain on change in fair value of preferred stock rights liability
    
    
    
    
    
    
    
    
    
    
    (2,765
    )Loss on extinguishment of notes payable
    
    
    
    
    
    
    
    
    
    
    13,285Other non-cash expenses (income)
    
    
    (8
    )
    
    
    11
    
    
    
    54Changes in operating assets and liabilities:Prepaid expenses and other current assets
    
    
    24
    
    
    
    446
    
    
    
    (319
    )Accounts payable
    
    
    (527
    )
    
    
    (238
    )
    
    
    699Accrued expenses and other current liabilities
    
    
    147
    
    
    
    223
    
    
    
    783Net cash used for operating activities
    
    
    (2,378
    )
    
    
    (3,839
    )
    
    
    (91,188
    )Cash Flows from Investing Activities:Purchases of property and equipment
    
    
    (5
    )
    
    
    (187
    )
    
    
    (4,737
    )Sales of property and equipment
    
    
    
    
    
    
    7
    
    
    
    168Purchases of short-term investments
    
    
    
    
    
    
    
    
    
    
    (17,886
    )Maturities of short-term investments
    
    
    
    
    
    
    
    
    
    
    17,886Net cash provided by (used for) investing activities
    
    
    (5
    )
    
    
    (180
    )
    
    
    (4,569
    )Cash Flows from Financing Activities:Proceeds from issuances of convertible preferred stock, net of costs
    
    
    
    
    
    
    
    
    
    
    68,917Proceeds from issuances of common stock
    
    
    
    
    
    
    5
    
    
    
    84,938Initial public offering costs
    
    
    
    
    
    
    
    
    
    
    (8,490
    )Proceeds from exercises of warrants
    
    
    
    
    
    
    
    
    
    
    263Repurchases of stock
    
    
    (550
    )
    
    
    
    
    
    
    (638
    )Proceeds from issuances of notes payable
    
    
    
    
    
    
    
    
    
    
    28,600Repayments of notes payable
    
    
    
    
    
    
    
    
    
    
    (100
    )Net cash provided by (used for) financing activities
    
    
    (550
    )
    
    
    5
    
    
    
    173,490Net increase (decrease) in cash and cash equivalents
    
    
    (2,933
    )
    
    
    (4,014
    )
    
    
    77,733Effect of foreign exchange rates
    
    
    (2
    )
    
    
    1
    
    
    
    1Cash and cash equivalents at beginning of period
    
    
    7,233
    
    
    
    81,747
    
    
    
    Cash and cash equivalents at end of period
    
    $
    4,298
    
    
    $
    77,734
    
    
    $
    77,734Supplemental Cash and Non-Cash InformationCash paid for interest
    
    $
    
    
    
    $
    
    
    
    $
    126Non-cash conversions of notes payable, accrued interest, note premiums and
discounts, preferred stock, non-voting common stock, preferred warrants,
and common warrants upon initial public offering in December 2010
    
    $
    
    
    
    $
    
    
    
    $
    120,349
  - 3 -




---



##### Table of Contents



REVA Medical, Inc.   Notes to Consolidated Financial Statements
 1. Background and Basis of Presentation
 Background :
   Basis of Presentation :
  Development Stage and Capital Resources :
 Initial Public Offering :
  - 4 -




---



##### Table of Contents



1. Background and Basis of Presentation
 Use of Estimates :
 Recent Accounting Pronouncements :
 2. Balance Sheet Details
 December 31,
    
    
    March 31,2010
    
    
    2011Property and equipment:Furniture and office equipment
    
    $
    351
    
    
    $
    368Laboratory equipment
    
    
    2,400
    
    
    
    2,559Leasehold improvements
    
    
    559
    
    
    
    5593,310
    
    
    
    3,486Accumulated depreciation and amortization
    
    
    (2,347
    )
    
    
    (2,458
    )$
    963
    
    
    $
    1,028Accrued expenses and other current liabilities:Accrued salaries and other employee costs
    
    $
    353
    
    
    $
    433Accrued operating expenses
    
    
    192
    
    
    
    345Accrued use taxes
    
    
    15
    
    
    
    26Deferred rent
    
    
    31
    
    
    
    21$
    591
    
    
    $
    825
  3. Income Taxes
  - 5 -




---



##### Table of Contents



4. Stock-Based Compensation
 The Plan :
  WeightedAverageOptions
    
    ExerciseOutstanding
    
    PriceBalance at December 31, 2010
    
    
    3,016,800
    
    
    $
    5.96Granted
    
    
    401,000
    
    
    $
    13.70Forfeited
    
    
    (800
    )
    
    $
    9.09Exercised
    
    
    (3,300
    )
    
    $
    1.29Balance at March 31, 2011
    
    
    3,413,700
    
    
    $
    6.87
   Stock Options and Restricted Stock to Employees :
   - 6 -




---



##### Table of Contents



4. Stock-Based Compensation
 Stock Options to Consultants :
 Three Months EndedMarch 31,2010
    
    2011Dividend yield
    
    
    0.0
    %
    
    
    0.0
    %Expected life  years
    
    
    6.00
    
    
    
    8.46Risk-free interest rate
    
    
    2.60
    %
    
    
    3.19
    %Expected volatility of common stock
    
    
    78.4
    %
    
    
    63.9
    %
 Non-Plan Options :
 5. Commitments and Contingencies
   6. Comprehensive Loss
  Three Months EndedMarch 31,2010
    
    
    2011Net loss
    
    $
    (2,976
    )
    
    $
    (5,133
    )Foreign currency translation adjustments
    
    
    (2
    )
    
    
    1Comprehensive loss
    
    $
    (2,978
    )
    
    $
    (5,132
    )
 - 7 -




---



##### Table of Contents



7. Net Loss Per Common Share
   Three Months EndedMarch 31,2010
    
    2011Convertible preferred stock
    
    
    13,853,882
    
    
    
    Common stock options
    
    
    1,560,500
    
    
    
    3,413,700Convertible notes payable and accrued interest
    
    
    3,157,446
    
    
    
    Convertible preferred stock warrants
    
    
    289,851
    
    
    
    Common stock warrants
    
    
    1,234,560
    
    
    
    20,096,239
    
    
    
    3,413,700
 - 8 -




---



##### Table of Contents



Item 2.
    
    Managements Discussion and Analysis of Financial Condition and Results of Operations
 You should read the following discussion and analysis of our financial condition and results
of operations in conjunction with our unaudited consolidated financial statements and related notes
thereto included in this Quarterly Report on Form 10-Q and with our consolidated financial
statements and the related notes thereto that are contained in our Annual Report on Form 10-K for
the year ended December 31, 2010. In addition to historical information, the following discussion
and analysis includes forward-looking information that involves risks, uncertainties, and
assumptions. Actual results and the timing of events could differ materially from those anticipated
by these forward-looking statements as a result of many factors, including those discussed under
Risk Factors elsewhere in this Form 10-Q and in our Form 10-K .
 Overview
 ReZolve tm
 ReZolve tm
 ReZolve tm
   - 9 -




---



##### Table of Contents



Key Components of our Results of Operations
  Research and Development Expenses:
 General and Administrative Expenses:
 Other Expense and Income:
 Critical Accounting Policies and Estimates
  - 10 -




---



##### Table of Contents



Research and Development Costs:
 Income Taxes:
 Stock-Based Compensation:
 - 11 -




---



##### Table of Contents



Results of Operations
 Comparison of the Three Months Ended March 31, 2010 and 2011
  Three Months EndedMarch 31,
    
    
    %2010
    
    
    2011
    
    
    Change(In thousands)Research and development expense
    
    $
    1,863
    
    
    $
    3,241
    
    
    
    74
    %General and administrative expense
    
    $
    368
    
    
    $
    1,928
    
    
    
    >100
    %Interest income
    
    $
    1
    
    
    $
    46
    
    
    
    >100
    %Interest expense
    
    $
    389
    
    
    $
    
    
    
    
    (100
    %)Loss on change in fair value of preferred stock warrant liability
    
    $
    375
    
    
    $
    
    
    
    
    (100
    %)Other income (expense)
    
    $
    18
    
    
    $
    (10
    )
    
    
    >(100
    %)Cumulative dividends on Series H convertible preferred stock
    
    $
    655
    
    
    $
    
    
    
    
    (100
    %)
 ReZolve tm
      - 12 -




---



##### Table of Contents



Liquidity and Capital Resources
 Sources of Liquidity
     Cash Flows
  Three Months EndedMarch 31,2010
    
    
    2011(In thousands)Net cash used for operating activities
    
    $
    (2,378
    )
    
    $
    (3,839
    )Net cash used for investing activities
    
    $
    (5
    )
    
    $
    (180
    )Net cash provided by (used for) financing activities
    
    $
    (550
    )
    
    $
    5Effect of foreign exchange rates
    
    $
    (2
    )
    
    $
    1Net decrease in cash and cash equivalents
    
    $
    (2,935
    )
    
    $
    (4,013
    )
 Net Cash Flow from Operating Activities
   - 13 -




---



##### Table of Contents



Net Cash Flow from Investing Activities
  Net Cash Flow from Financing Activities
   Operating Capital and Capital Expenditure Requirements
 ReZolve tm
   ReZolve tm
 
    
    the time and effort it will take to successfully complete the development and testing of
the ReZolvetm stent;
    
    the time and effort it will take to identify, develop, and scale-up manufacturing
processes;
    
    the scope, enrollment rate, and costs of our human clinical trials;
    
    the scope of research and development for any of our other product opportunities;
    
    the cost of filing and prosecuting patentable technologies and defending and enforcing our
patent and other intellectual property rights;
    
    the terms and timing of any collaborative, licensing, or other arrangements that we may
establish;
    
    the requirements, cost, and timing of regulatory approvals;
 - 14 -




---



##### Table of Contents




    
    the cost and timing of establishing sales, marketing, and distribution capabilities;
    
    the cost of establishing clinical and commercial supplies of our products and any products
that we may develop;
    
    the effect of competing technological and market developments; and
    
    the cost and ability to license technologies for future development.
  Contractual Obligations, Commitments, and Contingencies
  Payments Due by Period(In thousands)Total
    
    
    Under 1 Year
    
    
    Over 1 YearOperating lease obligations
    
    $
    182
    
    
    $
    182
    
    
    $
    Purchase obligations
    
    $
    457
    
    
    $
    457
    
    
    $
    Employment
agreements
    
    $
    450
    
    
    $
    450
    
    
    $
    Total contractual obligations
    
    $
    1,089
    
    
    $
    1,089
    
    
    $
    
 Off-Balance Sheet Arrangements
  Recent Accounting Pronouncements
  
 Item 3. Quantitative and Qualitative Disclosures about Market Risk
 Interest Rate Sensitivity
  Foreign Currency Risk
  - 15 -




---



##### Table of Contents



Related Party Transactions
  
 Item 4. Controls and Procedures
 Evaluation of Disclosure Controls and Procedures
  Changes in Internal Control Over Financial Reporting
  - 16 -




---



##### Table of Contents



PART II. OTHER INFORMATION
 
 Item 1. Legal Proceedings
  
 Item 1A. Risk Factors
 Investing in our common stock or our CHESS Depository Interests (or CDIs) involves a high
degree of risk. Our Annual Report on Form 10-K for the year ended December 31, 2010 includes a
detailed discussion of our risk factors in the section, Item 1A. Risk Factors. Set forth below
are certain material changes from the risk factors previously disclosed in the Form 10-K . You
should carefully consider the risk factors discussed in our Form 10-K and in this Quarterly Report
on Form 10-Q , as well as our other public filings, before deciding whether to invest in our common
stock or CDIs. The occurrence of any of the items discussed in the Form 10-K or in this Form 10-Q
could harm our business, financial condition, results of operations, or growth prospects, any of
which could cause the trading price of our CDIs to decline and you may lose all or part of your
investment.
 Risks Related to Our Business
 We rely on specialized suppliers for certain components and processes in the manufacture of our
ReZolve tm stent.
 ReZolve tm
 
    
    we are not a major customer of many of our suppliers, and these suppliers may therefore
give other customers needs higher priority than ours;
    
    our suppliers have no contractual obligation to supply, and we are not obligated to
purchase, any components used in our ReZolvetm stent, which may result in
supply interruptions;
    
    our suppliers source raw materials through supply chains that periodically are unable to
provide needed materials in a timely manner, which may cause delays in providing critical
components to us;
    
    our polymer is complex and must be manufactured to extremely tight tolerances and
specifications with the result that our suppliers, especially new suppliers, may make errors
in manufacturing that could negatively affect the efficacy or safety of the
ReZolvetm stent or cause our components not to be delivered on time or at
all or to be delivered outside of specifications;
    
    the availability of second-source suppliers may be extremely limited or their
implementation as a supplier may be lengthy due to the tight tolerances and specifications
which we require for the ReZolvetm stent; and
    
    switching suppliers or changes to our service providers may require product redesign and
submission to the regulatory authorities to whom we are seeking approval for our
ReZolvetm stent.
 ReZolve tm
 Risks Related to Our CDIs and Common Stock
 Future sales of our common stock may depress our share price.
  - 17 -




---



##### Table of Contents



Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
 Unregistered Sales of Equity Securities
  Use of Proceeds from Registered Securities
   
    
    $40.0 million for research and development activities, including continuing development of
our ReZolvetm stent;
    
    $10.0 million for clinical trials;
    
    $4.0 million for building commercial infrastructure, including manufacturing capacity
expansion; and
    
    the balance for working capital and other general corporate purposes.
  - 18 -




---



##### Table of Contents



Item 3. Defaults upon Senior Securities
  
 Item 4. (Removed and Reserved)
 
 Item 5. Other Information
  
 Item 6. Exhibits
 
 - 19 -




---



##### Table of Contents



SIGNATURES
  REVA Medical, Inc.Date:  May 16, 2011
    /s/ Robert B. StockmanRobert B. StockmanChairman of the Board and Chief Executive Officer(Principal Executive Officer)Date: May 16, 2011
    /s/ Katrina L. ThompsonKatrina L. ThompsonChief Financial Officer and Secretary(Principal Accounting Officer) - 20 -




---



##### Table of Contents



INDEX TO EXHIBITS
 ExhibitNumber
    
    Description of Exhibits3.1
    
    Amended and Restated Certificate of Incorporation.*3.2
    
    Amended and Restated Bylaws to be effective upon completion of this offering.*4.1
    
    Form of Stock Certificate.*4.2
    
    Form of Amended and Restated Investors Rights Agreement, by and among REVA
Medical, Inc. and the holders of our preferred stock set forth therein.*10.1
    
    Telecom Business Center Business Lease between FSP Telecom Business Center
Limited Partnership and REVA Medical, Inc. dated December 18, 2001.*10.2
    
    First Amendment to Telecom Business Center Business Lease between FSP Telecom
Business Center Limited Partnership and REVA Medical, Inc. dated January 3,
2005.*10.3
    
    Second Amendment to Telecom Business Center Business Lease between ARI Commercial
Properties, Inc. and REVA Medical, Inc. dated February 18, 2006.*10.4
    
    Third Amendment to Telecom Business Center Business Lease between ARI Commercial
Properties, Inc. and REVA Medical, Inc. dated December 14, 2006.*10.5
    
    Fourth Amendment to Telecom Business Center Business Lease between ARI Commercial
Properties, Inc. and REVA Medical, Inc. dated May 7, 2008.*10.6
    
    Agreement and Plan of Merger, dated October 13, 2004, by and among REVA Medical,
Inc., Boston Scientific Corporation, RMI Acquisition Corp. and certain
stockholder representatives set forth therein.*10.7
    
    Amendment No. 1 to the Agreement and Plan of Merger, dated December 7, 2007, by
and among REVA Medical, Inc., Boston Scientific Corporation, RMI Acquisition
Corp. and certain stockholder representatives set forth therein.*10.8
    
    Securities Purchase Agreement between Boston Scientific Corporation and REVA
Medical, Inc. dated October 13, 2004.*10.9
    
    Amendment No. 1 to Securities Purchase Agreement between Boston Scientific
Corporation and REVA Medical, Inc. dated December 7, 2007.*10.10
    
    Distribution Option Agreement, dated December 7, 2007, by and between REVA
Medical, Inc. and Boston Scientific Corporation.*10.11
    
    Exclusive License Agreement Number between Rutgers, The State University of New
Jersey and REVA Medical, Inc. dated July 1, 2010.++*10.12
    
    Royalty and License Agreement between Integra/LifeSciences Corporation and REVA
Medical, Inc. dated February 2, 2004.++*10.13
    
    2001 Stock Option/Stock Issuance Plan.+*10.14
    
    Form of Stock Option Agreement.+*10.15
    
    Form of Addendum to Stock Option Agreement.+*10.16
    
    2010 Equity Incentive Plan.+*10.17
    
    Form of Stock Option Agreement.+*10.18
    
    Form of Stock Option Agreement entered into with Robert Thomas and Anne Keating.+*10.19
    
    Form of Director and Officer Indemnification Agreement.+*10.20
    
    Employment Agreement, dated July 1, 2010, by and between REVA Medical, Inc. and
Robert B. Stockman.+*10.21
    
    Employment Agreement, dated October 21, 2010, by and between REVA Medical, Inc.
and Robert Schultz.+*10.22
    
    Employment Agreement, dated October 21, 2010, by and between REVA Medical, Inc.
and Katrina Thompson.+*10.23
    
    Form of Offer Management Agreement between REVA Medical, Inc. and Inteq Limited.*10.24
    
    Form of CDI Subscription Application for non U.S. investors.*10.25
    
    Form of CDI Subscription Application for U.S. investors.*10.26
    
    Form of Escrow Deed between REVA Medical, Inc. and Computershare Investor
Services Pty Limited.*21.1
    
    List of Subsidiaries.*




---



##### Table of Contents



ExhibitNumber
    
    Description of Exhibits31.1
    
    Certification of Principal Executive Officer Required Under Rule 13a-14(a) and
15d-14(a) of the Securities Exchange Act of 1934, as amended.31.2
    
    Certification of Principal Financial Officer Required Under Rule 13a-14(a) and
15d-14(a) of the Securities Exchange Act of 1934, as amended.32.1
    
    Certification of Principal Executive Officer and Principal Financial Officer
Required Under Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended,
and 18 U.S.C. §1350.99.1
    
    Section 13 of the ASX Settlement Rules.*
 
 +
    
    Management Compensation Plan++
    
    Confidential Treatment Request*
    
    Filed as exhibits to the registrants Registration Statement
on Form S-1 (File No. 333-168852), effective November 15,
2010, and incorporated herein by reference.